Official Title: “Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness”

Certain lung disease medications can influence diagnostic tests and research investigations.

This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Study Type: Interventional

Study Design: Diagnostic, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment

Study Primary Completion Date: April 2008

Intervention(s) in this Clinical Trial

• Drug: ipratropium bromide
  • 2 puffs (40 micrograms) 2 puffs (0micrograms)
• Drug: placebo
  • Matched placebo

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 1
• Placebo Comparator: 2

Primary Measures

• methacholine PC20
  • Time Frame: 6hours and 12 hours post inhalation
    Safety Issue?: No

Inclusion Criteria:

• Diagnosis of asthma; stable and controlled
• FEV1 greater than or equal to 65% predicted

Exclusion Criteria:

• Concomitant lung disease other than asthma

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 19 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: University of Saskatchewan

Overall Clinical Trial Officials and Contacts

Donald W Cockcroft, MD Principal Investigator Department of Medicine University of Saskatchewan  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00605410

Study ID Number: BIO 07-161

ClinicalTrials.gov Identifier: NCT00605410

Health Authority: Canada: Health Canada